norfloxacin has been researched along with Cholera Infantum in 11 studies
Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 9.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 6.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| "In a coordinated, double-blind multi-centre trial, adults with symptoms of acute pyelonephritis were randomly assigned to receive a two-week course of oral treatment with either 400 mg norfloxacin twice daily or 1 g cefadroxil twice daily." | 5.06 | Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis. ( Englund, G; Lincoln, K; Nilsson, LG; Sandberg, T, 1990) |
| "We designed a prospective study to evaluate the incidence of Escherichia coli in stools at admission in patients with cirrhosis that had previously received norfloxacin as primary or secondary prophylaxis of spontaneous bacterial peritonitis (SBP) (group I, n = 28) vs those who did not (group II, n = 55)." | 3.70 | [Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination]. ( Aparicio, JR; Arroyo, A; Gutiérrez, A; Pérez-Mateo, M; Plaza, J; Such, J, 1999) |
| " We have previously demonstrated that the ability to suppress bacterial colonization of this site with oral norfloxacin prophylaxis (400 mg every 12 h) affects the incidence and distribution of aerobic gram-negative bacterial infections and the overall management of infectious complications in this patient population." | 3.67 | Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient. ( Dick, JD; Karp, JE; Merz, WG, 1988) |
| "Norfloxacin has been compared to placebo (136 patients), sulfamethoxazole plus trimethoprim (SXT, 72 patients) and oral vancomycin plus colistin (V/C, 61 patients) for the prevention of alimentary tract-associated infections during and after induction chemotherapy." | 2.66 | The tolerability profile of prophylactic norfloxacin in neutropenic patients. ( Corrado, ML; Hesney, M; Struble, WE, 1988) |
| "Aerobic gram negative bacterial infections occur commonly in patients with acute leukemia undergoing intensive chemotherapy-induced bone marrow aplasia, and often arise from the gastrointestinal (GI) tract." | 2.66 | Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract. ( Bamberger, BJ; Bartlett, JG; Burke, PJ; Hendricksen, C; Karp, JE; Laughon, B; Merz, WG; Redden, T; Saral, R, 1986) |
| "Norfloxacin was least active against Clostridium difficile (90% minimal inhibitory concentration, 128 micrograms/ml)." | 1.27 | In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens. ( Gadebusch, HH; Shungu, DL; Weinberg, E, 1983) |
| " Whether administered for moderate or protracted periods, norfloxacin has been relatively safe in animals over a wide range of doses." | 1.27 | Norfloxacin: review of safety studies. ( Corrado, ML; Hoagland, V; Peter, C; Sabbaj, J; Struble, WE, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (72.73) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shungu, DL | 1 |
| Weinberg, E | 1 |
| Gadebusch, HH | 1 |
| Aparicio, JR | 1 |
| Such, J | 1 |
| Gutiérrez, A | 1 |
| Pérez-Mateo, M | 1 |
| Plaza, J | 1 |
| Arroyo, A | 1 |
| Stahlmann, R | 1 |
| Sandberg, T | 1 |
| Englund, G | 1 |
| Lincoln, K | 1 |
| Nilsson, LG | 1 |
| Murray, BE | 1 |
| Neu, HC | 1 |
| Karp, JE | 2 |
| Dick, JD | 1 |
| Merz, WG | 2 |
| Corrado, ML | 2 |
| Struble, WE | 2 |
| Hesney, M | 1 |
| Hendricksen, C | 1 |
| Laughon, B | 1 |
| Redden, T | 1 |
| Bamberger, BJ | 1 |
| Bartlett, JG | 1 |
| Saral, R | 1 |
| Burke, PJ | 1 |
| Peter, C | 1 |
| Hoagland, V | 1 |
| Sabbaj, J | 1 |
| Mascellino, MT | 1 |
| Lorenzi, A | 1 |
| Bonanni, M | 1 |
| Iegri, F | 1 |
1 review available for norfloxacin and Cholera Infantum
| Article | Year |
|---|---|
Quinolones and the gastrointestinal tract.
Topics: Agranulocytosis; Anti-Infective Agents; Bacterial Infections; Biliary Tract Diseases; Diarrhea; Drug | 1989 |
3 trials available for norfloxacin and Cholera Infantum
| Article | Year |
|---|---|
Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Bacteriuria; Cefadroxil; Chi-Square Distr | 1990 |
The tolerability profile of prophylactic norfloxacin in neutropenic patients.
Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Colistin; Diarrhea; Gastrointestina | 1988 |
Infection management during antileukemia treatment-induced granulocytopenia: the role for oral norfloxacin prophylaxis against infections arising from the gastrointestinal tract.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Agranulocytosis; Bacterial Infections; Clinical Tr | 1986 |
7 other studies available for norfloxacin and Cholera Infantum
| Article | Year |
|---|---|
In vitro antibacterial activity of norfloxacin (MK-0366, AM-715) and other agents against gastrointestinal tract pathogens.
Topics: Anti-Bacterial Agents; Bacteria; Bacterial Infections; Digestive System; Drug Combinations; Drug Res | 1983 |
[Development of Escherichia coli strands resistant to quinolones in stools of patients with liver cirrhosis submitted to selective bowel decontamination].
Topics: Aged; Anti-Infective Agents; Antibiotic Prophylaxis; Escherichia coli; Escherichia coli Infections; | 1999 |
Clinical toxicological aspects of fluoroquinolones.
Topics: Anti-Infective Agents; Bacterial Infections; Cardiovascular Diseases; Central Nervous System Disease | 2002 |
Clinical use of the quinolones.
Topics: Anti-Infective Agents; Ciprofloxacin; Diarrhea; Enoxacin; Gastrointestinal Diseases; Humans; Naphthy | 1987 |
Systemic infection and colonization with and without prophylactic norfloxacin use over time in the granulocytopenic, acute leukemia patient.
Topics: Administration, Oral; Agranulocytosis; Bacterial Infections; Digestive System; Gastrointestinal Dise | 1988 |
Norfloxacin: review of safety studies.
Topics: Animals; Carcinogens; Drug Evaluation; Gastrointestinal Diseases; Humans; Mutagens; Nervous System D | 1987 |
Antimicrobial activity of norfloxacin in enteric and urinary tract infections: combined effect of norfloxacin with aminoglycosides, tetracycline and chloramphenicol.
Topics: Acinetobacter; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Chloramphenicol; Drug C | 1986 |